Cicor Group continues on its growth path and increases operating margin

The increase in the EBITDA margin by 1.2 percentage points year-on-year to 10.7% is also the result of the continued focus on the strategic markets, which contributed 84% to total revenue in the first half of the year (1st half 2022: 80%). The operating margin was also supported by a significant reduction in brokerage costs, which are passed on to customers without a significant mark-up. This impact had still diluted margins  in the prior-year period. In line with its strategy, Cicor is growing in businesses with low asset intensity. This has led to a 1.5 percentage point increase in Core EBIT margin to 7.6% and Core EBIT growth of 57.5% to CHF 15.2 million (1st half 2022: CHF 9.7 million, 6.1% margin). Core net profit increased by 86.5% to CHF 9.2 million (1st half 2022: CHF 4.9 million).

The shortage in the supply of materials has partially eased, enabling a reduction in inventories. A key focus of Cicor’s management is on reducing net working capital. As a result of the initial successes of these efforts, free cash flow (before acquisitions) improved to CHF 5.2 million in the reporting period (1st half of 2022: CHF -21.8 million).

EMS Division

With a sales growth of 32.5% to CHF 179.0 million (1st half 2022: CHF 135.1 million), Cicor continues to pursue its growth strategy. In addition to organic growth (13.0% adjusted for currency effects), the newly acquired companies in Germany contributed to this result. Both SMT Elektronik (now Cicor Deutschland), which was consolidated for only two months in the same period of 2022, and the EMS operations acquired from Phoenix Mecano (now Cicor Digital Elektronik) on January 1, 2023, performed very satisfactorily. On the other hand, the strong Swiss franc and lower brokerage costs, which were passed on to customers, had a slowing effect. In the previous year, broker costs had been more than CHF 1 million per month. This has fallen by around 60% in this reporting period.

The integration of the new Cicor companies in Germany is progressing as planned. Together with RHe Microsystems, Cicor has now created an EMS business in Germany with locally generated sales of around EUR 100 million annually. This makes Cicor one of the most important EMS providers in Europe’s largest electronics market, with a clear focus on core markets.

The division’s EBITDA margin reached a new record level of 11.4% (1st half 2022: 10.2%), driven by a further improved product mix, higher production capacity utilization, an underproportional increase in overhead costs and a reduction in the dilutive effect of passed on broker costs. As a result, EBITDA increased by 48% to CHF 20.4 million (1st half 2022: CHF 13.8 million).

In Vietnam, a newly acquired production building was opened in close proximity to the existing site. By doubling the floor space to around 12,000 square meters, adding a clean room for the production of miniaturized electronics and investing in a fourth automated PCB assembly line, Cicor is preparing for further growth. Customer commitments have been received for several important new ramp-ups, including the relocation of production volumes from China to Southeast Asia, which will increase Cicor’s market share.

AS Division

The AS Division reported a 11.5% decline in sales to CHF 20.6 million in the first half of the year (1st half 2022: CHF 23.3 million), representing 10.4% of Group sales (1st half 2022: 14.8%). Reduced shipments of printed circuit boards to medical customers and the expiry of a multi-year order for hybrid circuits contributed to the decline in sales. The EBITDA margin decreased to 11.8% (1st half 2022: 13.2%) due to capacity utilization effects.

In the reporting period, Cicor completed the acquisition of the thin-film business of AFT microwave GmbH in Backnang, Germany, as part of an asset deal effective as of March 1, 2023. This acquisition strengthens Cicor’s position as a leading supplier of thin-film substrates in the European market.

The AS Division business is expected to develop positively in the second half of the year, as demand for hybrid substrates from a customer in the medical technology sector is forecasted to increase significantly.

Outlook for the second semester and the full year 2023

The continued growth momentum in order intake and sales leads to higher expectations than previously communicated. Provided that there are no significant changes in the economic and geopolitical environment as well as in exchange rates, Cicor expects to achieve annual sales of CHF 380 to 410 million in 2023 (previous guidance: CHF 360 to 400 million) and an operating result at EBITDA level of CHF 40 to 45 million (previous guidance: EBITDA margin comparable with last year’s figure of 10.3 percent).

Cicor intends to continue on its growth path. The focus will remain on the European market for sophisticated development and production services for high-end electronics. Supported by long-term market growth and Cicor’s track record in integrating acquired companies, above-average growth rates in sales and operating profit should continue to be achieved in the future.

At the same time, Cicor is making significant efforts to achieve its ESG goals, for example by reducing the energy intensity of its business. To this end, Cicor’s managers have included ESG objectives in their performance target agreements.